Fibroblast activation protein: A potential therapeutic target in cancer
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
The concept of targeting antigens selectively expressed on the surface of tumor capillary endothelial cells or in tumor stroma has emerged as a promising strategy for cancer therapeutics. Identification of stromal targets for anticancer therapy and development of selective inhibitors of these targets are of great clinical interest. Fibroblast activation protein (FAP), a member of the serine protease family, selectively expressed in the stromal fibroblasts associated with epithelial cancers, whereas with low or undetectable expression in the resting fibroblasts of normal adult tissues. The proteolytic activity of FAP has been shown to support tumor growth and proliferation, making it a potential target for novel anticancer therapies, such as those by immune-based approaches.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumors: Wounds That Do Not Heal
Flier, J. S., Underhill, L. H., & Dvorak, H. F. (1986) · New England Journal of Medicine · doi:10.1056/nejm198612253152606 · Cited by 4,391 · cited 1×
“The growth of solid neoplasms beyond a diameter of 1–2 mm requires a supporting tumor stroma to ensure the supply of nutrients for tumor cells to survive and continuously grow.(1) Thus, immunization against epitopes expressed by the tumor stroma can also potentially suppress tumor growth.”
BackgroundSuppression of Antitumor Immunity by Stromal Cells Expressing Fibroblast Activation Protein–α
Kraman, M., Bambrough, P. J., Arnold, J. N., Roberts, E. W., Magiera, L., Jones, J. O., Gopinathan, A., Tuveson, D. A., & Fearon, D. T. (2010) · Science · doi:10.1126/science.1195300 · Cited by 1,134 · cited 1×
“In addition, depletion of FAP cells causes rapid hypoxic necrosis of both cancer and stromal cells in immunogenic tumors through a process involving interferon-c (IFN-c) and tumor necrosis factor a (TNF-a), which have previously been shown to be involved in the suppression of angiogenesis.(51) In corneal stroma, FAP c…”
BackgroundLoeffler, M. (2006) · Journal of Clinical Investigation · doi:10.1172/jci26532 · Cited by 633 · cited 1×
“the animals completely rejecting a tumor cell challenge.(68) This strategy opens a new venue for the combination of immunotherapies and chemotherapies.”
BackgroundLiao, D., Luo, Y., Markowitz, D., Xiang, R., & Reisfeld, R. A. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007965 · Cited by 437 · cited 2×
“CAFs are key modulators of the immune TME and that their elimination in vivo has profound effects on immune polarization in the TME.(64) Importantly, with highly restricted of FAP to CAFs, the development FAP-based immunotherapy could be optimized for anticancer therapy in a clinical setting.”
BackgroundAcharya, P. S., Zukas, A., Chandan, V., Katzenstein, A.-L. A., & Puré, E. (2006) · Human Pathology · doi:10.1016/j.humpath.2005.11.020 · Cited by 204
Cited by
Targeting the tumour stroma to improve cancer therapy
Valkenburg, K. C., de Groot, A. E., & Pienta, K. J. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0007-1 · Cited by 1,084
Wang, L.-C. S., Lo, A., Scholler, J., Sun, J., Majumdar, R. S., Kapoor, V., Antzis, M., Cotner, C. E., Johnson, L. A., Durham, A. C., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0027 · Cited by 653
Zhang, H., Yue, X., Chen, Z., Liu, C., Wu, W., Zhang, N., Liu, Z., Yang, L., Jiang, Q., Cheng, Q., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01860-5 · Cited by 424
Cancer associated fibroblasts: An essential role in the tumor microenvironment
Tao, L., Huang, G., Song, H., Chen, Y., & Chen, L. (2017) · Oncology Letters · doi:10.3892/ol.2017.6497 · Cited by 351
Prognostic relevance of cancer-associated fibroblasts in human cancer
Paulsson, J., & Micke, P. (2014) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2014.02.006 · Cited by 275
Xin, L., Gao, J., Zheng, Z., Chen, Y., Lv, S., Zhao, Z., Yu, C., Yang, X., & Zhang, R. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.648187 · Cited by 203
Fibroblast Activation Protein Cleaves and Inactivates Fibroblast Growth Factor 21
Dunshee, D. R., Bainbridge, T. W., Kljavin, N. M., Zavala-Solorio, J., Schroeder, A. C., Chan, R., Corpuz, R., Wong, M., Zhou, W., Deshmukh, G., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.710582 · Cited by 158
c-Ski activates cancer-associated fibroblasts to regulate breast cancer cell invasion
Wang, L., Hou, Y., Sun, Y., Zhao, L., Tang, X., Hu, P., Yang, J., Zeng, Z., Yang, G., Cui, X., et al. (2013) · Molecular Oncology · doi:10.1016/j.molonc.2013.08.007 · Cited by 43
Cancer-Associated Fibroblast Proteins as Potential Targets against Colorectal Cancers
Shah, R., Johnson, K. A., Lippert, A. E. L., Kraus, S. G., Emmerich, P. B., Pasch, C. A., Zhang, W., Matkowskyj, K. A., LeBeau, A. M., & Deming, D. A. (2024) · Cancers · doi:10.3390/cancers16183158 · Cited by 18
Gene Augmentation and Editing to Improve TCR Engineered T Cell Therapy against Solid Tumors
Lo Presti, V., Buitenwerf, F., van Til, N. P., & Nierkens, S. (2020) · Vaccines · doi:10.3390/vaccines8040733 · Cited by 14
Metadata
- Authors
- Liu, R., Li, H., Liu, L., Yu, J., & Ren, X.
- Venue
- Cancer Biology & Therapy
- Publisher
- Informa UK Limited
- Published
- 2012-02
- Volume
- 13
- Issue
- 3
- Pages
- 123-129
- ISSN
- 1538-4047 (ISSN-L)
- 1555-8576
- OpenAlex
- W1492166511
- Cited by
- 182
- References
- 5
- FWCI
- 5.68
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.